Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

Modulating the DIPG microenvironment with virus and complement inhibitors as ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most formidable challenges faced by pediatric oncologists. For the last 30 years, all treatment approaches for these type of tumors have failed, leaving a terrible prospect of survival at 5 years for these children virtually of zero. Thus, it is clear that new ...

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

Unlocking the translational potential of the DIPG epigenome for a ...

Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor with a very poor outlook, with an expected survival of one year. Lack of access to biological tissue sample continues to be the largest barrier to advancing treatment. In 2016, the World Health Organization (WHO) reclassified DIPG tumors as diffuse ...

OLIG2 Targeting in DIPG using the novel small molecular inhibitor ...

Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable brain stem glioma predominantly arising in young children, better options to treat this aggressive disease are urgently needed. Oligodendrocyte transcription factor 2 (OLIG2) is mostly expressed in restricted domains of the brain and spinal cord ventricular zone which give rise to oligodendrocytes and ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...